Acebrophylline - Polichem/Hyundai Pharmaceutical

Drug Profile

Acebrophylline - Polichem/Hyundai Pharmaceutical

Alternative Names: HOB-051

Latest Information Update: 14 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Polichem
  • Developer Hyundai Pharmaceutical; NovoTek; Polichem
  • Class Antiasthmatics; Bronchodilators; Small molecules; Xanthines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bronchitis

Most Recent Events

  • 01 Nov 2015 Phase-III clinical trials in Bronchitis in South Korea (PO, controlled release) (NCT02792946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top